INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Undergoing bilateral hip or knee replacement       │ Patients undergoing bilateral hip or knee          │      89 │
│                                                    │ replacement                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has uncontrolled hypertension with systolic BP \>  │ Patients with severe uncontrolled hypertension     │      89 │
│ 220mmHg or diastolic BP \> 120mmHg                 │ with systolic BP > 220mmHg or diastolic BP >       │         │
│                                                    │ 120mmHg                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has had an operative procedure involving the eye,  │ Patients who have had an operative procedure       │      92 │
│ ear, or central nervous system within one month    │ involving the eye, ear, or central nervous system  │         │
│                                                    │ within one month                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has necessary mental capacity to participate and   │ Patient has necessary mental capacity to           │      95 │
│ is able to comply with study protocol requirements │ participate and is able to comply with study       │         │
│                                                    │ protocol requirements                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concurrently enrolled in another active            │ Patients who are concurrently enrolled in another  │      95 │
│ interventional clinical trial testing a drug or    │ active interventional clinical trial testing a     │         │
│ intervention known or believed to interact with    │ drug or intervention known or believed to interact │         │
│ aspirin, warfarin, or rivaroxaban                  │ with aspirin, warfarin, or rivaroxaban             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a known diagnosis of defective hemostasis and  │ Patients with a known diagnosis of defective       │      95 │
│ past history of clinical bleeding requiring        │ hemostasis and past history of clinical bleeding   │         │
│ transfusion and treatment                          │ requiring transfusion and treatment                │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Has been previously enrolled                       │ Males and females 21 years of age or older         │      40 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Is pregnant or breastfeeding                       │ Patients undergoing bilateral hip or knee          │      42 │
│                                                    │ replacement                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Is not pregnant on the day of surgery              │ Males and females 21 years of age or older         │      43 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 21 Years                  │ Males and females 21 years of age or older         │      43 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Member of a vulnerable patient population          │ Vulnerable patient populations including prisoners │      45 │
│                                                    │ and institutionalized individuals                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has signed the consent form; and                   │ Patient is willing and able to give informed       │      52 │
│                                                    │ consent; and                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eligible for randomization to at least two of the  │ Patients who have a contraindication to two or     │      63 │
│ three study regimens                               │ more of the three study prophylaxis regimens       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ 21 years of age or older                           │ Males and females 21 years of age or older         │      73 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Body weight of less than 41 kilograms at baseline  │ Patients with an absolute body weight of less than │      73 │
│ visit                                              │ 41 kilograms (90.4 lbs) at baseline visit          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Is on chronic anticoagulation other than           │ Patients on chronic (longer than the prior 6       │      74 │
│ antiplatelet medications                           │ months) anticoagulation other than with            │         │
│                                                    │ antiplatelet medications                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Is willing to be randomized and participate in the │ Patient is willing to be randomized and            │      79 │
│ study                                              │ participate                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Undergoing elective primary, revision or second    │ Undergoing elective primary, revision, or second   │      80 │
│ stage re-implantation total hip/knee replacement   │ stage re-implantation total or uni compartmental   │         │
│ or uni-compartmental knee replacement or hip       │ knee replacement                                   │         │
│ resurfacing arthroplasty                           │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has documented gastrointestinal, cerebral, or      │ Patients with documented gastrointestinal,         │      84 │
│ other hemorrhage within 3 months                   │ cerebral, or other hemorrhage within 3 months of   │         │
│                                                    │ the operation                                      │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Concurrently enrolled in another active            │ Women who are pregnant or breastfeeding, as well   │      43 │
│ interventional clinical trial testing a drug or    │ as those of reproductive potential unless there is │         │
│ intervention known or believed to interact with    │ a negative urine pregnancy test on the day of      │         │
│ aspirin, warfarin, or rivaroxaban                  │ surgery                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Member of a vulnerable patient population          │ Vulnerable patient populations including prisoners │      45 │
│                                                    │ and institutionalized individuals                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Undergoing bilateral hip or knee replacement       │ Patients undergoing total hip or knee replacement  │      49 │
│                                                    │ who have been enrolled in this study for a prior   │         │
│                                                    │ hip or knee replacement                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has signed the consent form; and                   │ Patient is willing and able to give informed       │      52 │
│                                                    │ consent; and                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eligible for randomization to at least two of the  │ Patients who have a contraindication to two or     │      63 │
│ three study regimens                               │ more of the three study prophylaxis regimens       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Undergoing elective primary, revision or second    │ Undergoing elective primary, resurfacing           │      64 │
│ stage re-implantation total hip/knee replacement   │ arthroplasty, revision, or second stage re-        │         │
│ or uni-compartmental knee replacement or hip       │ implantation total hip replacement                 │         │
│ resurfacing arthroplasty                           │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ 21 years of age or older                           │ Males and females 21 years of age or older         │      73 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Body weight of less than 41 kilograms at baseline  │ Patients with an absolute body weight of less than │      73 │
│ visit                                              │ 41 kilograms (90.4 lbs) at baseline visit          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Is on chronic anticoagulation other than           │ Patients on chronic (longer than the prior 6       │      74 │
│ antiplatelet medications                           │ months) anticoagulation other than with            │         │
│                                                    │ antiplatelet medications                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Is willing to be randomized and participate in the │ Patient is willing to be randomized and            │      79 │
│ study                                              │ participate                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Undergoing elective primary, revision or second    │ Undergoing elective primary, revision, or second   │      80 │
│ stage re-implantation total hip/knee replacement   │ stage re-implantation total or uni compartmental   │         │
│ or uni-compartmental knee replacement or hip       │ knee replacement                                   │         │
│ resurfacing arthroplasty                           │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has documented gastrointestinal, cerebral, or      │ Patients with documented gastrointestinal,         │      84 │
│ other hemorrhage within 3 months                   │ cerebral, or other hemorrhage within 3 months of   │         │
│                                                    │ the operation                                      │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 68
Average Levenshtein Ratio of individual lines: 68.54838709677419
OverAll Ratio: 68.2741935483871
